Chang‐Ki Min

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem-Cell Transplantation

Byung‐Sik Cho, Seung‐Ah Yahng, Sung‐Eun Lee et al. · Transplantation · 2010 · 275 citations

Medicine, Hematology, Hematopathology +7

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia

Seok Lee, Yoo‐Jin Kim, Chang‐Ki Min et al. · Blood · 2005 · 195 citations · Full text

Medicine, Hematology, Oncology +12

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Naresh Bumma, Joshua Richter, Sundar Jagannath et al. · Journal of Clinical Oncology · 2024 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

S. J. Kim, Jae Wook Lee, Chang Wook Jung et al. · Haematologica · 2010 · 108 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15